EI

259.8

-1.03%↓

SAN

80.72

+2.25%↑

MRK1

109.9

-0.9%↓

SHL.DE

47.3

-0.55%↓

ARGX

651.8

+0.37%↑

EI

259.8

-1.03%↓

SAN

80.72

+2.25%↑

MRK1

109.9

-0.9%↓

SHL.DE

47.3

-0.55%↓

ARGX

651.8

+0.37%↑

EI

259.8

-1.03%↓

SAN

80.72

+2.25%↑

MRK1

109.9

-0.9%↓

SHL.DE

47.3

-0.55%↓

ARGX

651.8

+0.37%↑

EI

259.8

-1.03%↓

SAN

80.72

+2.25%↑

MRK1

109.9

-0.9%↓

SHL.DE

47.3

-0.55%↓

ARGX

651.8

+0.37%↑

EI

259.8

-1.03%↓

SAN

80.72

+2.25%↑

MRK1

109.9

-0.9%↓

SHL.DE

47.3

-0.55%↓

ARGX

651.8

+0.37%↑

Search

Laboratorios Farmaceuticos Rovi SA

Gesloten

SectorGezondheidszorg

59.65 -0.33

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

59.25

Max

59.85

Belangrijke statistieken

By Trading Economics

Inkomsten

3.9M

27M

Verkoop

4.8M

160M

K/W

Sectorgemiddelde

22.78

35.733

EPS

0.423

Dividendrendement

1.61

Winstmarge

16.767

Werknemers

2,188

EBITDA

4.2M

35M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+35.54% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.61%

3.13%

Volgende Winsten

6 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

196M

3B

Vorige openingsprijs

59.98

Vorige sluitingsprijs

59.65

Nieuwssentiment

By Acuity

25%

75%

74 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 sep 2025, 23:59 UTC

Acquisities, Fusies, Overnames

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 sep 2025, 22:02 UTC

Belangrijke Marktbewegers

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 sep 2025, 17:01 UTC

Belangrijke Marktbewegers

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 sep 2025, 17:01 UTC

Belangrijke Marktbewegers

Tron Shares Rise After New Investment From Bravemorning

8 sep 2025, 16:14 UTC

Belangrijke Marktbewegers

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 sep 2025, 16:13 UTC

Belangrijke Marktbewegers

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 sep 2025, 23:12 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 sep 2025, 23:12 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 sep 2025, 23:12 UTC

Marktinformatie

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 sep 2025, 22:56 UTC

Marktinformatie

Worst May Be Over for New Zealand Retailers -- Market Talk

8 sep 2025, 22:23 UTC

Marktinformatie

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 sep 2025, 21:51 UTC

Marktinformatie

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 sep 2025, 21:47 UTC

Belangrijke Marktbewegers

Microsoft Signs $17.4B AI Deal With Nebius

8 sep 2025, 21:33 UTC

Acquisities, Fusies, Overnames

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 sep 2025, 21:20 UTC

Acquisities, Fusies, Overnames

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 sep 2025, 21:19 UTC

Acquisities, Fusies, Overnames

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 sep 2025, 21:18 UTC

Acquisities, Fusies, Overnames

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 sep 2025, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

8 sep 2025, 19:33 UTC

Marktinformatie

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 sep 2025, 19:22 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 sep 2025, 19:02 UTC

Marktinformatie

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 sep 2025, 18:24 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 sep 2025, 18:24 UTC

Marktinformatie

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 sep 2025, 17:29 UTC

Marktinformatie

Mexican Inflation Seen Little Changed in August -- Market Talk

8 sep 2025, 16:59 UTC

Marktinformatie
Acquisities, Fusies, Overnames

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 sep 2025, 16:36 UTC

Marktinformatie

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 sep 2025, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

8 sep 2025, 16:16 UTC

Winsten

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 sep 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 sep 2025, 16:04 UTC

Marktinformatie

Global Equities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Laboratorios Farmaceuticos Rovi SA Prognose

Koersdoel

By TipRanks

35.54% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 80.85 EUR  35.54%

Hoogste 90 EUR

Laagste 71.7 EUR

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Laboratorios Farmaceuticos Rovi SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technische score

By Trading Central

51.1 / N/ASteun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

74 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat